Amalgamated Bank Sells 943 Shares of Certara, Inc. (NASDAQ:CERT)

Amalgamated Bank trimmed its position in shares of Certara, Inc. (NASDAQ:CERT) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,156 shares of the company’s stock after selling 943 shares during the period. Amalgamated Bank’s holdings in Certara were worth $338,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of CERT. Versant Capital Management Inc lifted its position in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after acquiring an additional 1,866 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after acquiring an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Certara during the fourth quarter worth $47,000. Sterling Capital Management LLC lifted its position in shares of Certara by 57.2% during the fourth quarter. Sterling Capital Management LLC now owns 7,209 shares of the company’s stock worth $77,000 after acquiring an additional 2,624 shares in the last quarter. Finally, Portside Wealth Group LLC purchased a new stake in shares of Certara during the first quarter worth $104,000. 73.96% of the stock is owned by institutional investors.

Certara Trading Down 3.6%

NASDAQ CERT opened at $11.09 on Friday. The stock’s 50-day simple moving average is $11.42 and its two-hundred day simple moving average is $11.86. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $16.93. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -554.50 and a beta of 1.43.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter last year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. Research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on CERT shares. Morgan Stanley started coverage on Certara in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 target price on the stock. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. KeyCorp increased their price objective on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Tuesday, May 6th. Finally, Robert W. Baird increased their price objective on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Moderate Buy” and an average price target of $15.71.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.